Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: BioCardia is a clinical-stage company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its primary platforms include the CardiAMP autologous mononuclear cell therapy for ischemic heart failure (HFrEF) and chronic myocardial ischemia (CMI), and the CardiALLO allogeneic mesenchymal stem cell (MSC) therapy for HFrEF and acute respiratory distress syndrome (ARDS). The company also commercializes the Helix biotherapeutic delivery system and Morph catheter products.
Key Financial Metrics
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Revenue | $58 | $477 |
| Research & Development Expenses | $4,387 | $7,726 |
| Selling, General & Administrative Expenses | $3,672 | $4,395 |
| Operating Loss | $(8,001) | $(11,644) |
| Net Loss | $(7,946) | $(11,571) |
| Cash and Cash Equivalents (Year End) | $2,371 | $1,103 |
| Accumulated Deficit | $(160,121) | $(152,175) |
| Net Cash Used in Operating Activities | $(8,026) | $(9,974) |
| Net Cash Provided by Financing Activities | $9,300 | $3,726 |
Note: The filing does not provide specific margin percentages or debt figures beyond lease liabilities. The company has no long-term debt.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 88% to $58,000 from $477,000 in 2023, driven by the timing of collaboration agreement revenues which depend on partner development activities.
- Expense Reduction: Total costs and expenses decreased by approximately 34% to $8.1 million from $12.1 million. R&D expenses dropped significantly due to reduced personnel and clinical costs following the completion of the CardiAMP Cell Therapy Heart Failure Trial. SG&A expenses also declined due to personnel realignment and cost reductions.
- Improved Liquidity Position: Cash and cash equivalents increased to $2.4 million from $1.1 million, primarily due to net proceeds of approximately $9.3 million from financing activities, including a September 2024 registered offering and ATM sales.
- Stock Structure: The company effected a 1-for-15 reverse stock split in May 2024.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
- Clinical Milestones: Principal results for the CardiAMP HF Trial (115 randomized patients) are scheduled for presentation at the American College of Cardiology (ACC) Scientific Sessions on March 30, 2025. The CardiAMP HF II trial (250 patients) is active, and the Chronic Myocardial Ischemia trial (343 patients) is ongoing.
- Capital Needs: Management believes current cash of approximately $2.4 million is insufficient to fund planned expenditures beyond May 2025. The company plans to raise additional capital through equity, debt, or collaborations.
Risks and Contingencies
- Going Concern: The financial statements include a "substantial doubt" disclosure regarding the company's ability to continue as a going concern due to recurring losses and negative cash flows.
- Regulatory Uncertainty: The CardiAMP Cell Therapy System is the first cardiac cell-based therapy regulated via the FDA Premarket Approval (PMA) pathway. Approval is not guaranteed, and the process is uncertain.
- Nasdaq Compliance: The company is not currently in compliance with the Nasdaq continued listing requirement for minimum stockholders' equity of $2.5 million, creating a risk of delisting.
- Intellectual Property: Success depends on maintaining patent protection and avoiding infringement claims.
Unusual Items
- Financing Activity: In September 2024, the company completed a registered offering raising $7.2 million in gross proceeds. In February 2024, a private placement raised $875,000.
- Grant Liability: A $468,000 grant liability from TEDCO is recorded as refundable until qualifying costs are incurred.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure funding before May 2025 to avoid operational disruption.
- Clinical Data Presentation: Monitor the March 30, 2025, presentation of CardiAMP HF Trial results for efficacy and safety data.
- Nasdaq Status: Track the company's progress in regaining compliance with Nasdaq stockholders' equity requirements to avoid delisting.
- Regulatory Pathway: Confirm FDA acceptance of the PMA pathway for the CardiAMP system and any requests for additional data.
- Revenue Sustainability: Assess the volatility of collaboration revenue and the timeline for commercial product sales.